Taiwan University's RS-D7 Receives FDA Orphan Drug Designation for Treating Fatal Multiple System Atrophy (MSA)

Professor Wen-Sung Lai's research team at National Taiwan University has successfully developed a new drug, RS-D7, by combining years of research, literature data, and artificial intelligence technology. RS-D7 works by inhibiting D-amino acid oxidase (DAO) to enhance NMDA receptor activity, effectively improving motor and cognitive deficits in patients with Multiple System Atrophy (MSA). This breakthrough drug has the potential to become a groundbreaking treatment for MSA.